글루카곤 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global glucagon market size is expected to reach USD 670.31 Million in 2034 from USD 358.83 Million in 2025, growing at a CAGR of 7.19 during 2026-2034.This market is experiencing steady growth due to the increasing prevalence of diabetes and the rising need for emergency treatments for severe hypoglycemia. Glucagon is a hormone used to raise blood glucose levels and is commonly administered during hypoglycemic emergencies. The growing global diabetic population is a major factor driving market growth, as the need for effective and rapid treatment options continues to rise. Additionally, increasing awareness about diabetes management and emergency preparedness is supporting the adoption of glucagon products.

Growth drivers include advancements in pharmaceutical formulations and delivery systems that improve ease of use and effectiveness. The development of ready-to-use glucagon kits and nasal formulations has enhanced patient convenience and accessibility. Healthcare providers are increasingly recommending glucagon as part of diabetes management plans, further supporting market growth. Furthermore, the expansion of healthcare infrastructure and improved access to medical services in emerging regions are contributing to increased adoption.

Looking ahead, the glucagon market is expected to witness continuous innovation and development. Companies are likely to focus on developing more user-friendly and stable formulations. The integration of digital health technologies and connected devices will further improve patient monitoring and treatment outcomes. As awareness and healthcare access continue to improve, the market is anticipated to grow steadily.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Route of Administration

• Injectable
• Inhalation

By Application

• Hypoglycemia
• Diagnostic Aid

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Novo Nordisk A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals Inc., Xeris Biopharma Holdings Inc., ILS Inc., United Biotech (P) Limited, Zealand Pharma A/S, Taj Pharmaceuticals Limited., Eli Lilly and Company, Bayer AG, Torrent Pharmaceuticals Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GLUCAGON MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Route Of Administration
• 4.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Inhalation Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GLUCAGON MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Hypoglycemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnostic Aid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GLUCAGON MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Drug Stores & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GLUCAGON MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Route Of Administration
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Route Of Administration
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Route Of Administration
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Route Of Administration
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Route Of Administration
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GLUCAGON INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novo Nordisk A/S
  • 9.2.2 Fresenius SE & Co. KGaA
  • 9.2.3 Amphastar Pharmaceuticals Inc
  • 9.2.4 Xeris Biopharma Holdings Inc
  • 9.2.5 ILS Inc
  • 9.2.6 United Biotech (P) Limited
  • 9.2.7 Zealand Pharma A/S
  • 9.2.8 Taj Pharmaceuticals Limited
  • 9.2.9 Eli Lilly And Company
  • 9.2.10 Bayer AG
  • 9.2.11 Torrent Pharmaceuticals Ltd